Market Research Report
Surgical Site Infections (SSI) - Market Insights, Epidemiology and Market Forecast - 2028
|Published by||DelveInsight Business Research LLP||Product code||911513|
|Published||Content info||147 Pages
Delivery time: 1-2 business days
|Surgical Site Infections (SSI) - Market Insights, Epidemiology and Market Forecast - 2028|
|Published: September 1, 2019||Content info: 147 Pages||
DelveInsight's 'Surgical Site Infections (SSI) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SSI in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Surgical Site Infections from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
The DelveInsight Surgical Site Infection epidemiology report gives the thorough understanding of the SSI by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Surgical Site Infection in the US, Europe, and Japan.
The Surgical Site Infection (SSI) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the current and forecasted trends by exploring numerous studies, public databases, and views of key opinion leaders. This part of the DelveInsight report provides the total number of surgical procedures performed each year and incidence of surgical site infections, along with their trends and assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total surgical procedures, total incidence cases of SSI, and type-specific incidence cases) scenario of Surgical Site Infection (SSI) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight, total incident population of Surgical Site Infection (SSI) in 7 major markets was found to be 1,101,182 in 2017.
This segment of the Surgical Site Infection report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, advantages and disadvantages of each included drug and the latest news and press releases.
At present, therapeutic classes of drugs contributing towards the market size of SSI includes, the topical or oral or injectable prophylactic antibiotics used for preoperative, intraoperative and postoperative procedures. The prophylactic therapy drug market is dominated by generic antibiotics, and most common drugs include antibiotics such as: Cefazolin, Vancomycin, Cefuroxime, Clindamycin, Cefotetan, Metronidazole and Gentamicin. On other hand Surgical Site Infection (SSI) Treatment drug market is based on antibiotics such as Vancomycin and Linezolid (Cardiothoracic / related leg SSI) and Tigecycline IV (Abdominal SSI).
The emerging drugs offer certain improvement in treatment and prevention approached relative to the current medicinal products. These include Prophylactic Therapy D-PLEX100 and XF-73 under-development by PolyPid Ltd. And Destiny Pharma respectively, while Delafloxacin (Menarini Group) being the only upcoming therapy for patient with incisional, superficial or deep, surgical site infection treatment. Detailed chapter for these upcoming therapies have also been covered in the report.
The Surgical Site Infection market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better approach.
This segment gives a through detail of market trend of each marketed drug class and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the treatment market of Surgical Site Infection in 7MM was found to be USD 855 million in 2017.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.